Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 198-205

  Li, Ping ^a   Ferrario, Carlos M ^a   Brosnihan, K Bridget ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II antagonist; Aorta, SHR; Endothelium; Endothelium derived contracting factor; Losartan; Platelet; Prostaglandins; Thromboxane A2

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; CANDESARTAN; CANDESARTAN HEXETIL; LISINOPRIL; LOSARTAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; ENDOTHELINS; ENDOTHELIUM, VASCULAR; IMIDAZOLES; LOSARTAN; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, INBRED SHR; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; TETRAZOLES; THROMBOXANE A2; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0031826398     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00005     Document Type: Article

References (42)

1. Timmermans PBWM, Wong PC, Chiu AT, Smith RD. The preclinical basis of the therapeutic evaluation of losartan. J Hypertens 1995;13:S1-13.
2. Goodfriend TL, Elliott ME, Gatt KJ. Angiotensin receptors and their antagonists. Drug Ther 1996;334:1649-54.
3. 1-receptor antagonist losartan in hypertension. J New Dev Clin Med 1996;13:195-206.
4. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
5. Liu YJ. Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays. Eur J Pharmacol 1993;240:147-54.
6. Rhaleb NE, Rouissi N, Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 1991;17:480-4.
7. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266:R1273-8.
8. Ohlstein EH, Gellai M, Brooks DP, et al. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther 1992;262:595-601.
9. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995;26:236-43.
10. Pals DT, Masucci FD, Denning GS, Jr., Sipos F, Fessler DC. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res 1971;29:673-81.
11. Sweet CS, Gross DM, Arbegast PT, et al. Antihypertensive activity of N-((S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 1981;216:558-66.
12. 3H)losartan in the rat liver. Biochem Pharmacol 1993;46:1653-60.
13. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin release. Am J Hypertens 1991;4:228-33.
14. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997;281: 1065-70.
15. 2 receptor-mediated pulmonary hypertension by a non-peptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994;268:747-68.
16. Corii C, Bernard S, Schott C, Stolte J-C. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995;26:688-92.
17. 2 (TP) receptors. Prostaglandins 1992;44:89-99.
18. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 1990;15:699-703.
19. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990;15:475-81.
20. 2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension 1992;19:795-8.
21. 2-mediated mechanism of vascular contraction in hypertensive rats: relation to lipoxygenase and prostacyclin synthase activities. Circ Res 1994;74:197-205.
22. Yokoyama K, Kudo I, Nakamura H, Inoue K. A possible role for extracellular bicarbonate in U-46619-induced rat platelet aggregation. Thromb Res 1994;74:369-76.
23. Brunner HR, Delacretaz E, Nussberger J, Burnier M, Waeber B. Angiotensin II antagonists DuP 753 and TCV 116. J Hypertens 1994;12:S29-34.
24. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985;234:435-41.
25. Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS. Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol 1986;48:307-20.
26. Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase in canine veins. Am J Physiol 1985;248:H432-7.
27. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
28. Chiu AT, McCall DE, Price WA, et al. In vitro pharmacology of DuP753. Am J Hypertens 1991;4:282S-7S.
29. Wong PC, Price WA, Chiu AT, et al. Non-peptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:719-25.
30. Wong PC, Price WA Jr, Chiu AT, et al. Non-peptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, and orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
31. Sachinidis A, Ko Y, Weisser P, et al. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin Il-induced responses in vascular smooth muscle cells. J Hypertens 1993;11:155-62.
32. Maeso R, Navarro J, Munoz-Garcia R, et al. Losartan but not captopril reduces catecholamine constrictor response in aortic rings from SHR [Abstract]. Hypertension 1995;25:52.
33. Lin L, Mistry M, Stier CT Jr, Nasjletti A. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension 1991;17:517-25.
34. Himmelstein SI, Klotman PE. The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats. Am J Physiol 1989;257:F190-6.
35. Keen HL, Brands MW, Smith MJ Jr, Shek EW, Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension 1997;29:310-4.
36. 2 receptors maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat. Am J Physiol 1996;271:R891-6.
37. Konieczkowski M, Dunn MJ, Stork JE, Hassid A. Glomerular synthesis of prostaglandins and thromboxane in spontaneously hypertensive rats. Hypertension 1983;5:446-52.
38. Rapoport RM, Williams SP. Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1996;28:64-75.
39. Tesfamariam B. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide. J Hypertens 1994;12:41-7.
40. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
41. Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity. Cardiovasc Drugs Ther 1996;10:511-8.
42. Tallant EA, Ferrario CM. Drug evaluation: cardiovascular and renal biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs 1996;5:1-14.